BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Alharthi J, Eslam M. Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr 2021;10:696-8. [PMID: 34760977 DOI: 10.21037/hbsn-21-269] [Reference Citation Analysis]
2 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
3 Li MD. Clock-modulated checkpoints in time-restricted eating. Trends Mol Med 2022;28:25-35. [PMID: 34801412 DOI: 10.1016/j.molmed.2021.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
5 Li YM, Zhao SY, Zhao HH, Wang BH, Li SM. Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. Evid Based Complement Alternat Med 2021;2021:8920757. [PMID: 34956386 DOI: 10.1155/2021/8920757] [Reference Citation Analysis]
6 Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers 2022;2022:1254014. [PMID: 35811662 DOI: 10.1155/2022/1254014] [Reference Citation Analysis]
7 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 37.0] [Reference Citation Analysis]
8 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 146] [Cited by in F6Publishing: 122] [Article Influence: 73.0] [Reference Citation Analysis]
9 Fouad Y, Gomaa A, Attia D. The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt. Ther Adv Endocrinol Metab 2021;12:20420188211054678. [PMID: 34733466 DOI: 10.1177/20420188211054678] [Reference Citation Analysis]
10 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Reference Citation Analysis]
11 [DOI: 10.1101/2020.08.20.20176214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
13 Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64. [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 30.5] [Reference Citation Analysis]
14 Zhang X, Asllanaj E, Amiri M, Portilla-Fernandez E, Bramer WM, Nano J, Voortman T, Pan Q, Ghanbari M. Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review. Eur J Clin Invest 2021;51:e13479. [PMID: 33350463 DOI: 10.1111/eci.13479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61. [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Hegazy MA, Abd ALgwad I, Abuel Fadl S, Sayed Hassan M, Ahmed Rashed L, Hussein MA. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity. Diabetes Metab Syndr Obes 2021;14:2247-54. [PMID: 34040409 DOI: 10.2147/DMSO.S291595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Yin Q, Li Y, Zhou Z, Li X, Li M, Liu C, Dong D, Wang G, Zhu M, Yang J, Jin Y, Guo L, Yin Y. RPA1 controls chromatin architecture and maintains lipid metabolic homeostasis. Cell Rep 2022;40:111071. [PMID: 35830798 DOI: 10.1016/j.celrep.2022.111071] [Reference Citation Analysis]
18 Neri CR, Scapaticci S, Chiarelli F, Giannini C. Liver Steatosis: A Marker of Metabolic Risk in Children. Int J Mol Sci 2022;23:4822. [PMID: 35563210 DOI: 10.3390/ijms23094822] [Reference Citation Analysis]
19 Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res 2021;167:105484. [PMID: 33771699 DOI: 10.1016/j.phrs.2021.105484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Gao Y, Zhang H, Lirussi F, Garrido C, Ye XY, Xie T. Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. Biochem Pharmacol 2020;182:114224. [PMID: 32956642 DOI: 10.1016/j.bcp.2020.114224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Metwally M, Berg T, Tsochatzis EA, Eslam M. Translation Reprogramming as a Novel Therapeutic Target in MAFLD. Adv Biol (Weinh) 2022;:e2101298. [PMID: 35240009 DOI: 10.1002/adbi.202101298] [Reference Citation Analysis]
22 Maldonato BJ, Vergara AG, Yadav J, Glass SM, Paragas EM, Li D, Lazarus P, McClay JL, Ning B, Daly AK, Russell LE. Epigenetics in Drug Disposition & Drug Therapy: Symposium Report of the 24th North American Meeting of the International Society for the Study of Xenobiotics (ISSX). Drug Metab Rev 2022;:1-38. [PMID: 35876105 DOI: 10.1080/03602532.2022.2101662] [Reference Citation Analysis]
23 Rauff B, Amar A, Chudhary SA, Mahmood S, Tayyab GUN, Hanif R. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. Arch Virol 2021;166:1047-56. [PMID: 33528661 DOI: 10.1007/s00705-020-04901-2] [Reference Citation Analysis]
24 Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George J. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35710982 DOI: 10.1038/s41575-022-00635-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li MD, Xin H, Yuan Y, Yang X, Li H, Tian D, Zhang H, Zhang Z, Han TL, Chen Q, Duan G, Ju D, Chen K, Deng F, He W; Biological Rhythm Academic Consortium in Chongqing (BRACQ). Circadian Clock-Controlled Checkpoints in the Pathogenesis of Complex Disease. Front Genet 2021;12:721231. [PMID: 34557221 DOI: 10.3389/fgene.2021.721231] [Reference Citation Analysis]
26 Smyth LJ, Patterson CC, Swan EJ, Maxwell AP, McKnight AJ. DNA Methylation Associated With Diabetic Kidney Disease in Blood-Derived DNA. Front Cell Dev Biol 2020;8:561907. [PMID: 33178681 DOI: 10.3389/fcell.2020.561907] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yang H, Feng L, Xu L, Jiang D, Zhai F, Tong G, Xing Y, Wada K. Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis. BioMed Research International 2022;2022:1-15. [DOI: 10.1155/2022/4801695] [Reference Citation Analysis]
28 Clayton M, Fabrellas N, Luo J, Alghamdi MG, Hafez A, Qadiri TA, Owise N, Attia D. From NAFLD to MAFLD: Nurse and allied health perspective. Liver Int 2021;41:683-91. [DOI: 10.1111/liv.14788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
29 Mendez-sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-ferrer J, Restrepo JC, Padilla-machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology & Hepatology 2021;6:65-72. [DOI: 10.1016/s2468-1253(20)30340-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 34] [Article Influence: 62.0] [Reference Citation Analysis]
30 Hu S, Lian PP, Hu Y, Zhu XY, Jiang SW, Ma Q, Li LY, Yang JF, Yang L, Guo HY, Zhou H, Yang CC, Meng XM, Li J, Li HW, Xu T, Zhou H. The Role of IL-35 in the Pathophysiological Processes of Liver Disease. Front Pharmacol 2020;11:569575. [PMID: 33584256 DOI: 10.3389/fphar.2020.569575] [Reference Citation Analysis]